Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
9.41
+0.05 (0.53%)
At close: Sep 26, 2025, 4:00 PM EDT
9.35
-0.06 (-0.64%)
After-hours: Sep 26, 2025, 7:53 PM EDT
Prothena Corporation Employees
Prothena Corporation had 163 employees as of December 31, 2024. The number of employees decreased by 10 or -5.78% compared to the previous year.
Employees
163
Change (1Y)
-10
Growth (1Y)
-5.78%
Revenue / Employee
$63,442
Profits / Employee
-$1,858,399
Market Cap
506.54M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 163 | -10 | -5.78% |
Dec 31, 2023 | 173 | 46 | 36.22% |
Dec 31, 2022 | 127 | 45 | 54.88% |
Dec 31, 2021 | 82 | 16 | 24.24% |
Dec 31, 2020 | 66 | 15 | 29.41% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PRTA News
- 4 weeks ago - Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference - Business Wire
- 4 weeks ago - Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program - Business Wire
- 7 weeks ago - Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 7 weeks ago - Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
- 2 months ago - Prothena to Report Second Quarter 2025 Financial Results on August 4 - Business Wire
- 3 months ago - Prothena Announces Corporate Restructuring - Business Wire
- 3 months ago - Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - Business Wire
- 4 months ago - Why Is Prothena Stock Trading Lower On Tuesday? - Benzinga